Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Bearish -50

Truist Cuts PT on Boston Scientific Corporation (BSX) to $92 From $95 – Here’s Why

AI-generated analysis

📉 Truist lowered its price target on Boston Scientific Corporation (BSX) from $95 to $92 while maintaining a Buy rating.

📈 UBS cut its price target for BSX from $120 to $105 but reiterated its Buy recommendation.

💊 Analysts expect positive trial data for the CHAMPION-AF readout, which could lead to an expanded WATCHMAN indication.

📊 Boston Scientific reported Q4 2025 net sales of $5.286 billion, representing a 15.9% growth on a reported basis.

📅 For full year 2025, the company generated net sales of $20.074 billion, up 19.9% on a reported basis.

⚙️ The company's operations are divided into two main segments: Cardiovascular and MedSurg.

❤️ The Cardiovascular segment covers Cardiology and Peripheral Interventions.

🔪 The MedSurg segment comprises Urology, Endoscopy, and Neuromodulation.

⚠️ One analyst note suggests AI stocks may offer greater upside potential and less downside risk compared to BSX.

🇺🇸 Some commentary highlights the benefits of AI stocks from Trump-era tariffs and onshoring trends.

📊 Organic sales growth for Q4 2025 was reported at 12.7%.

🌿 Organic sales growth for full year 2025 was reported at 15.8%.

Bullish Signals
  • Truist and UBS both maintain a Buy rating on Boston Scientific (NYSE: BSX), demonstrating continued institutional confidence in the stock despite price target adjustments.
  • Boston Scientific reported strong financial growth with Q4 net sales of $5.286 billion, representing a 15.9% increase compared to the prior year.
  • The company's full year 2025 revenue reached $20.074 billion, which is up nearly 20% on a reported basis and 15.8% on an organic basis.
  • Investors anticipate positive trial data for the CHAMPION-AF device that could lead to an expanded indication for the WATCHMAN technology.
  • The firm's diversified operations across Cardiovascular and MedSurg segments, including Urology, Endoscopy, and Neuromodulation, provide broad market exposure.
Risk Factors
  • Truist analysts cut the price target on Boston Scientific (BSX) from $95 to $92, downgrading expectations for the stock despite reiterating a Buy rating.
  • UBS also reduced its price target on BSX significantly from $120 to $105 on March 17, indicating concern over valuation or alternative opportunities.
  • The Truist analyst note explicitly states that other AI stocks offer greater upside potential and carry less downside risk than Boston Scientific.
  • Truist suggests investors might find more attractive short-term gains in undervalued AI stocks benefiting from Trump-era tariffs rather than in medical device manufacturers.
  • Investor sentiment is being diverted away from BSX toward competing sectors like artificial intelligence, potentially suppressing long-term valuation support.
Full Analysis
Truist Financial recently lowered its price target on Boston Scientific Corporation (NYSE:BSX) from $95 to $92 while reaffirming its Buy rating. This adjustment occurred on March 18 ahead of a key clinical trial readout for the CHAMPION-AF procedure, which Truist expects will yield positive data at endpoints and potentially expand the FDA-approved indication for their WATCHMAN left atrial appendage occluder device. Concurrently, UBS also downgraded its price target on the same stock to $105 from $120 on March 17, though they maintained a Buy rating. Boston Scientific reported strong financial performance in fiscal Q4 and full year 2025. For the quarter, net sales reached $5.286 billion, representing a 15.9% increase on a reported basis, 14.3% growth operationally, and 12.7% organic growth compared to the prior year. Full year 2025 results showed net sales of $20.074 billion, marking a 19.9% reported increase, 19.2% operational growth, and 15.8% organic expansion. The company continues its focus on interventional medical procedures through its Cardiovascular segment (covering Cardiology and Peripheral Interventions) and MedSurg segment (including Urology, Endoscopy, and Neuromodulation). The article concludes with a separate recommendation from the publication suggesting readers consider AI stocks over Boston Scientific for greater upside potential and less downside risk, specifically noting benefits from potential Trump-era tariffs and onshoring trends. This section serves as promotional content directing readers to free reports on other equities rather than additional analysis of Boston Scientific itself. The core investment updates regarding price targets and financial results remain the central focus of the piece.